Clinical Oversight Review Board (CORB) Criteria for Prescribing

Zenocutuzumab (Bizengri)

Non-Formulary **Zenocutuzmab** (**Bizengri**) requires a clinical review. Appropriateness of therapy will be based on the following criteria:

Initiation (new start) criteria:

- Prescribed by a hematologist or oncologist
- · Age greater than or equal to 18 years
- Presence of NRG1 Gene Fusion mutation
- Patients have a diagnosis of one of the following:
 - Locally advanced or metastatic non-small cell lung cancer (NSCLC) AND
 - Received at least 1 prior systemic treatment for NSCLC
 - Locally advanced or metastatic pancreatic cancer AND
 - Received at least 1 prior systemic treatment for pancreatic cancer

<u>Criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously:</u>

- Prescribed by a hematologist or oncologist
- Age greater than or equal to 18 years
- Presence of NRG1 Gene Fusion mutation
- Patients have a diagnosis of one of the following:
 - Locally advanced or metastatic non-small cell lung cancer (NSCLC) AND
 - Received at least 1 prior systemic treatment for NSCLC
 - Locally advanced or metastatic pancreatic cancer AND
 - Received at least 1 prior systemic treatment for pancreatic cancer

•

<u>Criteria for new members entering Kaiser Permanente already taking the</u> medication who have not been reviewed previously:

- Prescribed by a hematologist or oncologist
- Age greater than or equal to 18 years
- Presence of NRG1 Gene Fusion mutation
- Patients have a diagnosis of one of the following:
 - Locally advanced or metastatic non-small cell lung cancer (NSCLC) AND
 - Received at least 1 prior systemic treatment for NSCLC
 - Locally advanced or metastatic pancreatic cancer AND
 - Received at least 1 prior systemic treatment for pancreatic cancer

kp.org

Revised: 08/14/25 Effective: 10/16/25 All plans offered and underwritten by Kaiser Foundation Health Plan of the Northwest




Clinical Oversight Review Board (CORB) Criteria for Prescribing

Zenocutuzumab (Bizengri)

kp.org

Revised: 08/14/25 Effective: 10/16/25





All plans offered and underwritten by